Trevi Therapeutics is a biopharmaceutical firm that develops and distributes medical treatments for neurologically mediated ailments. Its phase IIb/III clinical trial is focused on Haduvio, a nalbuphine-based formulation designed for the treatment of chronic coughs and pruritus in those with idiopathic pulmonary fibrosis. With a license agreement with Endo Pharmaceuticals, it is empowered to develop nalbuphine hydrochloride-based products in any formulation.